Medigen Vaccine Biologics (ROCO:6547) Cyclically Adjusted PS Ratio: (As of Aug. 19, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6547 Medigen Vaccine Biologics Corp ROCO:6547
68 GF Score
Price NT$52.20
GF Value NT$52.09
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Medigen Vaccine Biologics Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Medigen Vaccine Biologics  (ROCO:6547) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Medigen Vaccine Biologics Cyclically Adjusted PS Ratio Related Terms


Medigen Vaccine Biologics Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Medigen Vaccine Biologics's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medigen Vaccine Biologics Cyclically Adjusted PS Ratio Chart

Medigen Vaccine Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 11.20 12.31

Medigen Vaccine Biologics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.42 12.38 12.31 18.78 0.00

ROCO:6547 vs VRTX, REGN, RVMD: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Medigen Vaccine Biologics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medigen Vaccine Biologics Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medigen Vaccine Biologics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Medigen Vaccine Biologics's Cyclically Adjusted PS Ratio falls into.


ROCO:6547
68GF Score
Medigen Vaccine Biologics Corp ROCO:6547
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medigen Vaccine Biologics Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Medigen Vaccine Biologics's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Medigen Vaccine Biologics's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.36/333.9520*333.9520
=0.360

Current CPI (Jun. 2026) = 333.9520.

Medigen Vaccine Biologics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.000 241.428 0.000
201612 0.000 241.432 0.000
201703 0.000 243.801 0.000
201706 0.000 244.955 0.000
201709 0.000 246.819 0.000
201712 0.000 246.524 0.000
201803 0.000 249.554 0.000
201806 0.000 251.989 0.000
201809 0.000 252.439 0.000
201812 0.000 251.233 0.000
201903 0.000 254.202 0.000
201906 0.003 256.143 0.004
201909 0.000 256.759 0.000
201912 0.002 256.974 0.003
202003 0.002 258.115 0.003
202006 0.004 257.797 0.005
202009 0.011 260.280 0.014
202012 0.023 260.474 0.029
202103 0.010 264.877 0.013
202106 0.003 271.696 0.004
202109 3.886 274.310 4.731
202112 6.407 278.802 7.674
202203 1.022 287.504 1.187
202206 0.039 296.311 0.044
202209 0.006 296.808 0.007
202212 0.072 296.797 0.081
202303 0.000 301.836 0.000
202306 0.000 305.109 0.000
202309 0.671 307.789 0.728
202312 0.521 306.746 0.567
202403 0.178 312.332 0.190
202406 0.517 314.175 0.550
202409 0.739 315.301 0.783
202412 0.392 315.605 0.415
202503 0.351 319.799 0.367
202506 0.441 322.561 0.457
202509 0.638 324.800 0.656
202512 0.447 324.054 0.461
202603 0.322 330.213 0.326
202606 0.360 333.952 0.360

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Medigen Vaccine Biologics (ROCO:6547) Overvalued in 2026?

Based on GuruFocus' analysis, Medigen Vaccine Biologics stock appears to be overvalued. The current stock price of NT$52.20 is trading 0.2% above its estimated GF Value™ of NT$52.09. GuruFocus considers Medigen Vaccine Biologics to be Fairly Valued.

Key valuation signals for ROCO:6547:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: NT$52.09 vs. price of NT$52.20 (0.2% above fair value)
  • GF Score™: 68/100 with 2 warning signs

No single metric tells the full story. See the ROCO:6547 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Medigen Vaccine Biologics Business Description

Address 302 No. 68, Shengyi 3rd Road, Hsinchu County, Zhubei, TWN, 30261
Medigen Vaccine Biologics Corp is engaged in the research, development and wholesale of vaccine and biopharmaceutical, medical devices wholesale and retail, etc. Its products include dengue vaccine, anti-RSV biosimilars, COVID-19 vaccines, enterovirus A71 vaccine, and influenza vaccine QIZ. It operates business only in a single industry in Taiwan.
68GF Score

Get the complete analysis for ROCO:6547

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$52.20
Price
NT$52.09
GF Value